AnaptysBio Inc
ANABHealthcare|Biotechnology|USA
$66.46
-0.20 (-0.30%)
Tangible Book
$0.44
About
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
Stock Price
+282.2%(1Y)
Pipeline Summary
9 total trials0
Phase 1
8
Phase 2
0
Phase 3
0
Phase 4
Unknown: 1Active: 2Completed: 5Terminated: 1
Active Trials (2)
A Study of Efficacy and Safety of Rosnilimab in Subjects with Moderate to Severe Rheumatoid Arthritis (RENOIR)
NCT06041269Rheumatoid Arthritis
Phase 2Active
Enrollment: 420 participants
A Study of Efficacy and Safety of Rosnilimab in Subjects With Moderate to Severe Ulcerative Colitis (ROSETTA)
NCT06127043Ulcerative Colitis
Phase 2Active
Enrollment: 132 participants
BioScore
4.3/10
Cautious
Ownership
Recent Insider Trades
Schmid John P.SELL
2026-03-3020,645 shares @ $56.11
Faga DanielSELL
2026-03-2717,679 shares @ $61.61
LOUMEAU ERIC JSELL
2026-02-1110,000 shares @ $54
Marquet MagdaSELL
2026-01-1511,000 shares @ $48.23
Lizzul Paul F.SELL
2026-01-083,650 shares @ $44.71
Data last updated: Jul 12, 2026, 07:40 PM